Yang Bai,Albert S Agustinus,Shira Yomtoubian,Cem Meydan,Dylan R McNally,Liron Yoffe,Melissa J Hubisz,Marvel Tranquille,Sneha Pramod,Christy Hong,Magdalena L Plasilova,Aakanksha R Kapoor,Arshdeep Singh,Henry Withers,Lukas E Dow,Ashley M Laughney,Bhavneet Bhinder,Olivier Elemento,Ari M Melnick,Samuel F Bakhoum,Vivek Mittal
{"title":"Epigenetic regulation of chromosomal instability by EZH2 methyltransferase.","authors":"Yang Bai,Albert S Agustinus,Shira Yomtoubian,Cem Meydan,Dylan R McNally,Liron Yoffe,Melissa J Hubisz,Marvel Tranquille,Sneha Pramod,Christy Hong,Magdalena L Plasilova,Aakanksha R Kapoor,Arshdeep Singh,Henry Withers,Lukas E Dow,Ashley M Laughney,Bhavneet Bhinder,Olivier Elemento,Ari M Melnick,Samuel F Bakhoum,Vivek Mittal","doi":"10.1158/2159-8290.cd-25-0947","DOIUrl":null,"url":null,"abstract":"Chromosomal instability (CIN) and epigenetic reprogramming are central drivers of breast cancer progression, yet the mechanisms connecting them remain elusive. We uncover a direct role of EZH2 histone methyltransferase in promoting CIN in triple-negative breast cancer (TNBC). Across breast cancers, EZH2 expression correlates with copy number alterations, and its catalytic activity is associated with increased CIN in metastasis-initiating cells. Pharmacological EZH2 inhibition suppressed CIN, revealing an unexpected vulnerability. Integrated chromatin and transcriptome profiling identified Tankyrase (TNKS), a poly(ADP-ribose) polymerase, as a direct transcriptional target of EZH2. Mechanistically, EZH2-mediated TNKS suppression disrupts CPAP (centrosomal P4.1-associated protein), driving centrosome overduplication, multipolar mitosis and exacerbated CIN. In vivo, CIN suppression is a critical mechanism underlying the anti-metastatic effects of EZH2 inhibition. These findings delineate a previously unrecognized epigenetic mechanism governing CIN and establish EZH2 inhibitors as the first therapeutic agents capable of directly suppressing CIN, underscoring the need for trials with metastasis-focused endpoints.","PeriodicalId":9430,"journal":{"name":"Cancer discovery","volume":"22 1","pages":""},"PeriodicalIF":33.3000,"publicationDate":"2025-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer discovery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1158/2159-8290.cd-25-0947","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Chromosomal instability (CIN) and epigenetic reprogramming are central drivers of breast cancer progression, yet the mechanisms connecting them remain elusive. We uncover a direct role of EZH2 histone methyltransferase in promoting CIN in triple-negative breast cancer (TNBC). Across breast cancers, EZH2 expression correlates with copy number alterations, and its catalytic activity is associated with increased CIN in metastasis-initiating cells. Pharmacological EZH2 inhibition suppressed CIN, revealing an unexpected vulnerability. Integrated chromatin and transcriptome profiling identified Tankyrase (TNKS), a poly(ADP-ribose) polymerase, as a direct transcriptional target of EZH2. Mechanistically, EZH2-mediated TNKS suppression disrupts CPAP (centrosomal P4.1-associated protein), driving centrosome overduplication, multipolar mitosis and exacerbated CIN. In vivo, CIN suppression is a critical mechanism underlying the anti-metastatic effects of EZH2 inhibition. These findings delineate a previously unrecognized epigenetic mechanism governing CIN and establish EZH2 inhibitors as the first therapeutic agents capable of directly suppressing CIN, underscoring the need for trials with metastasis-focused endpoints.
期刊介绍:
Cancer Discovery publishes high-impact, peer-reviewed articles detailing significant advances in both research and clinical trials. Serving as a premier cancer information resource, the journal also features Review Articles, Perspectives, Commentaries, News stories, and Research Watch summaries to keep readers abreast of the latest findings in the field. Covering a wide range of topics, from laboratory research to clinical trials and epidemiologic studies, Cancer Discovery spans the entire spectrum of cancer research and medicine.